The purpose of the Phase 1 portion of this study was to determine the dose of LY2603618 that
can be safely administered 24 hours after gemcitabine treatment. This dose was then used for
the Phase 2 portion of the study. The Phase 2 portion of the study evaluated whether
LY2603618, when administered 24 hours after gemcitabine therapy, was an effective treatment
for participants with pancreatic cancer.